Get the Stockscreener App
25.58
4.92%
1.20
After Hours:
25.69
0.11
+0.43%
Arcutis Biotherapeutics Inc stock is traded at $25.58, with a volume of 1.78M.
It is up +4.92% in the last 24 hours and up +19.98% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$24.38
Open:
$24.62
24h Volume:
1.78M
Relative Volume:
1.14
Market Cap:
$3.20B
Revenue:
$415.62M
Net Income/Loss:
$-2.38M
P/E Ratio:
-900.70
EPS:
-0.0284
Net Cash Flow:
$16.92M
1W Performance:
+18.76%
1M Performance:
+19.98%
6M Performance:
-11.64%
1Y Performance:
+90.47%
1-Day Range:
$24.04
$25.62
1-Week Range:
$21.72
$25.62
52-Week Range:
$12.97
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
25.58 | 3.05B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
[144] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis (ARQT) director amends filing to correct indirect share count - Stock Titan
Arcutis Biotherapeutics touts ZORYVE growth, FDA catalysts and cash-flow positive status - MSN
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) reports Q1 loss, beats revenue estimates - MSN
GW&K Investment Management LLC Sells 163,461 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status - sharewise.com
Arcutis (ARQT) director receives RSU grant and 16,667-share stock option - Stock Titan
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Arcutis Stockholders Approve Proposals at 2026 Meeting - TipRanks
Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay - Stock Titan
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors - GlobeNewswire Inc.
Geode Capital Management LLC Has $79.97 Million Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Arcutis hires receive 44,000 restricted stock units - Stock Titan
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 sees revenue beat, EPS miss - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com
ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Chart - ChartMill
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - StreetInsider
New Expert Consensus Provides Age-Specific Guidance for - GlobeNewswire
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Hillsdale Investment Management Inc. Invests $5.21 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
ARQT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
(ARQT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37 - Moomoo
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Globe and Mail
Insiders At Arcutis Biotherapeutics Sold US$4.4m In Stock, Alluding To Potential Weakness - Moomoo
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144: Patrick Burnett reports share dispositions - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144 lists 435 vested shares for resale - Stock Titan
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):